E Colajori - JoVE Visualize

Showing results (1-10 of 7) with videos related to

Pageof 1

Sort By:

Haematologia|January 1, 1984

Spleen alterations in hairy cell leukemia: a scanning electron microscopic studyG Lambertenghi-Deliliers, D Soligo, E Colajori, et al.

Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982

Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological featuresR Mozzana, L Baldini, A Neri, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study GroupG Brufman, E Colajori, N Ghilezan, et al.

European Journal of Cancer (Oxford, England : 1990)|March 12, 2003

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validationD Moneta, C Geroni, O Valota, et al.

Tumori|April 30, 1994

Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Oncology Society)A Villar-Grimalt, E Aranda, B Massutí, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational studyS P Ackland, A Anton, G P Breitbach, et al.

Lancet (London, England)|February 20, 2007

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.

Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:

Pageof 1

Haematologia|January 1, 1984

Spleen alterations in hairy cell leukemia: a scanning electron microscopic studyG Lambertenghi-Deliliers, D Soligo, E Colajori, et al.

Bollettino Dell'Istituto Sieroterapico Milanese|January 1, 1982

Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological featuresR Mozzana, L Baldini, A Neri, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1997

Doubling epirubicin dose intensity (100 mg/m2 versus 50 mg/m2) in the FEC regimen significantly increases response rates. An international randomised phase III study in metastatic breast cancer. The Epirubicin High Dose (HEPI 010) Study GroupG Brufman, E Colajori, N Ghilezan, et al.

European Journal of Cancer (Oxford, England : 1990)|March 12, 2003

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validationD Moneta, C Geroni, O Valota, et al.

Tumori|April 30, 1994

Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Oncology Society)A Villar-Grimalt, E Aranda, B Massutí, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2001

Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational studyS P Ackland, A Anton, G P Breitbach, et al.

Lancet (London, England)|February 20, 2007

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialR C Coombes, L S Kilburn, C F Snowdon, et al.

Pageof 1